MEDIGEN, INC.  

Medigen and its partners have a unique experience in vaccine development against many public health threats.

Here are selected publications by staff and partners.

Cancer

Venezuelan equine encephalitis replicon immunization overcomes intrinsic tolerance and elicits effective anti-tumor immunity to the 'self' tumor-associated antigen, neu in a rat mammary tumor model. Nelson EL, Prieto D, Alexander TG, Pushko P, Lofts LA, Rayner JO, Kamrud KI, Fralish B, Smith JF. Breast Cancer Res Treat. 2003 Dec;82(3):169-83. [PDF]

Cutting edge: permissive MHC class II allele changes the pattern of antitumor immune response resulting in failure of tumor rejection. Klyushnenkova EN, Kouiavskaia DV, Berard CA, Alexander RB. J Immunol. 2009 Feb 1;182(3):1242-6.

HIV

Incorporation of high levels of chimeric human immunodeficiency virus envelope glycoproteins into virus-like particles. Wang BZ, Liu W, Kang SM, Alam M, Huang C, Ye L, Sun Y, Li Y, Kothe DL, Pushko P, Dokland T, Haynes BF, Smith G, Hahn BH, Compans RW. J Virol. 2007 Oct;81(20):10869-78.

Influenza

Intranasal vaccination with 1918 influenza virus-like particles protects mice and ferrets from lethal 1918 and H5N1 influenza virus challenge. Perrone LA, Ahmad A, Veguilla V, Lu X, Smith G, Katz JM, Pushko P, Tumpey TM. J Virol. 2009 Jun;83(11):5726-34.

Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. Bright RA, Carter DM, Crevar CJ, Toapanta FR, Steckbeck JD, Cole KS, Kumar NM, Pushko P, Smith G, Tumpey TM, Ross TM. PLoS One. 2008 Jan 30;3(1):e1501.

Evaluation of influenza virus-like particles and Novasome adjuvant as candidate vaccine for avian influenza. Pushko P, Tumpey TM, Van Hoeven N, Belser JA, Robinson R, Nathan M, Smith G, Wright DC, Bright RA. Vaccine. 2007 May 22;25(21):4283-90. [PDF]

HPV

Evaluation of HBs, HBc, and frCP virus-like particles for expression of human papillomavirus 16 E7 oncoprotein epitopes. Pumpens P, Razanskas R, Pushko P, Renhof R, Gusars I, Skrastina D, Ose V, Borisova G, Sominskaya I, Petrovskis I, Jansons J, Sasnauskas K. Intervirology. 2002;45(1):24-32.

Synthesis and assembly of virus-like particles of human papillomaviruses type 6 and type 16 in fission yeast Schizosaccharomyces pombe. Sasagawa T, Pushko P, Steers G, Gschmeissner SE, Hajibagheri MA, Finch J, Crawford L, Tommasino M. Virology. 1995 Jan 10;206(1):126-35.

HBV

Recombinant core particles of hepatitis B virus exposing foreign antigenic determinants on their surface. Borisova GP, Berzins I, Pushko PM, Pumpens P, Gren EJ, Tsibinogin VV, Loseva V, Ose V, Ulrich R, Siakkou H, et al. FEBS Lett. 1989 Dec 18;259(1):121-4.

Determination of the minimal length of preS1 epitope recognized by a monoclonal antibody which inhibits attachment of hepatitis B virus to hepatocytes. Sominskaya I, Pushko P, Dreilina D, Kozlovskaya T, Pumpens P. Med Microbiol Immunol. 1992;181(4):215-26.

Ebola, Marburg filoviruses

Evaluation in nonhuman primates of vaccines against Ebola virus. Geisbert TW, Pushko P, Anderson K, Smith J, Davis KJ, Jahrling PB. Emerg Infect Dis. 2002 May;8(5):503-7.

Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates. Hevey M, Negley D, Pushko P, Smith J, Schmaljohn A. Virology. 1998 Nov 10;251(1):28-37.

Lassa arenavirus

Safety, immunogenicity, and efficacy of the ML29 reassortant vaccine for Lassa fever in small non-human primates. Lukashevich IS, Carrion R Jr, Salvato MS, Mansfield K, Brasky K, Zapata J, Cairo C, Goicochea M, Hoosien GE, Ticer A, Bryant J, Davis H, Hammamieh R, Mayda M, Jett M, Patterson J. Vaccine. 2008 Sep 26;26(41):5246-54.

Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses. Pushko P, Geisbert J, Parker M, Jahrling P, Smith J. J Virol. 2001 Dec;75(23):11677-85.

Influenza virus. Courtesy: CDC

Expression of Prostate-Specific Antigen (PSA), Medigen, Inc.